Aware Super’s AbbVie ABBV Stock Holding History

Aware Super’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$40.4M	Buy	160,675 +75,023	+88%	+$16.1M	0.57%	35
2026 Q1	$18.6M	Buy	+85,652	New	+$19M	0.28%	94
2025 Q3	$20.6M	Hold	88,936	–	–	0.28%	97
2025 Q2	$16.5M	Hold	88,936	–	–	0.24%	109
2025 Q1	$18.6M	Sell	88,936 -53,166	-37%	-$10.3M	0.32%	98
2024 Q4	$25.3M	Buy	+142,102	New	+$26.1M	0.4%	80
2023 Q4	$20.8M	Buy	+91,020	New	+$13.3M	0.28%	94

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Aware Super's ABBV Position: Q2 2026 in Review

Aware Super increased its AbbVie (ABBV) stake by 88% in Q2 2026, buying an estimated $16.1M and bringing the position to 160,675 shares worth $40.4M. The position accounts for 0.57% of the portfolio, ranked #35.

Aware Super first reported a position in ABBV in Q4 2023 and has held it in 7 quarters since. 4,214 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Aware Super held 160,675 shares of AbbVie worth $40.4M as of Q2 2026.
Aware Super bought 75,023 AbbVie shares in Q2 2026, an estimated $16.1M.
AbbVie made up 0.57% of Aware Super's portfolio in Q2 2026, its #35 holding.
Aware Super first reported a position in AbbVie in Q4 2023 and has held it in 7 quarters since.
4,214 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Aware Super's 13F filing for Q2 2026, filed 29 Jul 2026.